Clinical Trial Detail

NCT ID NCT03331341
Title Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors University of Washington
Indications

Hodgkin's lymphoma

Therapies

Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine

Age Groups: senior adult

No variant requirements are available.